Accessibility Menu
Voyager Therapeutics logo

Voyager Therapeutics(NASDAQ) VYGR

Market Cap$183.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-83%
5 Year-5%
1 Year-6%
1 Month-16%
$3.02
-0.82%
-0.02Today
Voyager Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 3.002026-07-29
Voyager Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.23%USD 3.102026-07-22
1 month-16.2%USD 3.582026-06-29
3 month-19.57%USD 3.732026-04-30
Year to date-23.66%USD 3.932025-12-31
1 year-6.25%USD 3.202025-07-29
3 year-66.96%USD 9.082023-07-28
5 year-4.76%USD 3.152021-07-30
Since inception-82.87%USD 17.752015-11-11

Voyager Therapeutics Financials at a Glance

Market Cap

$183.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$36.49M

Net Income (TTM)

-$116.64M

EPS (TTM)

-$1.98

P/E Ratio

-1.54

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$3.02

Volume

590,608.478

Open

$3.02

Previous Close

$3.00

Daily Range

$2.99 - $3.15

52-Week Range

$2.88 - $5.55

Estimated Earnings Date

Aug 5, 2026

VYGR News

radiologist of Oncology institute is examing MRI scans

2 Biotech Stocks That Could Make You Richer

James HalleyJul 14, 2023
gene therapy

Why Voyager Therapeutics Stock Is Sinking This Week

George Budwell, PhDJan 20, 2023
Scientist, monitors with DNA

Pfizer and Novartis Are Betting On This Under-the-Radar Biotech. Should You?

Keith SpeightsMar 19, 2022
gene therapy

Why Voyager Therapeutics Stock Is Sinking Today

George Budwell, PhDOct 13, 2020
dna-model-getty

Parkinson's Disease Patients Get Long-Term Benefits From Experimental Gene Therapy

Cory RenauerSep 11, 2020
financial health stethoscope money cash hundred bills medical healthcare

Is Now a Good Time To Buy Neurocrine Biosciences?

James HalleyMay 14, 2020
doctor-female-patient

3 Biotechs That Have Doubled This Year (Acquisition Next?)

Brian Orelli, PhDJul 2, 2019
coins in hands stock up

Here's Why Voyager Therapeutics Stock Rose as Much as 13% Today

Maxx ChatskoMar 4, 2019
Page 1

VYGR: Motley Fool Moneyball Superscore

55

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Voyager Therapeutics

Voyager creates gene therapies to treat brain and nerve diseases. They use human genetics to make long-term medical treatments. These medicines help people with Alzheimer's and Parkinson's disease.

Fixing the Brain's Code

  • TRACER Platform: RNA-based screening tool used to discover delivery vehicles for gene therapies; focuses on crossing the blood-brain barrier.
  • Alzheimer's Pipeline: Research programs including VY1706 and VY7523 designed to target and silence specific proteins in the brain.
  • NeuroShuttle Platform: Non-viral delivery system used to transport different types of medicine into the central nervous system.
  • Partnered Programs: Collaborative research targeting Friedreich's ataxia, Huntington's disease, and Gaucher disease with external drugmakers.

Strategic Partnerships and Moves

  • Established a license and research collaboration with Novartis Pharma AG in December 2023 to develop therapies for Huntington's disease.
  • Partnered with Neurocrine Biosciences in January 2023 to advance gene therapies for rare genetic targets.
  • Licensed delivery technology to Alexion (AstraZeneca Rare Disease) for the treatment of an undisclosed neurological target.
  • Collaborated with Transition Bio in June 2025 to discover small molecules for the treatment of amyotrophic lateral sclerosis.

Crossing the Brain Barrier

Voyager utilizes its TRACER discovery platform to identify specific receptors that help medicines enter the brain more effectively. The company builds strategic partnerships with global pharmaceutical firms to fund and advance its clinical research pipeline.

Q1 2026 by the Numbers

  • Total revenue fell to $2.6 million in Q1 2026, down 59.9% from Q1 2025.
  • Net loss was $27.9 million in Q1 2026, which narrowed (improved) by 9.9% year-over-year.
  • Operating cash flow was negative $33.4 million in Q1 2026, narrowing (improving) 11.8% from Q1 2025.
  • Cash, cash equivalents, and marketable securities totaled $171.7 million as of March 31, 2026.

Final Word

Voyager has transitioned from a technology platform focus to a developer with multiple clinical and partnered programs. Strategic collaborations with major drugmakers provide the funding necessary for its research into complex central nervous system diseases.

AI Generated • May 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

141

CEO

Alfred W. Sandrock, Jr., MD

Website

www.voyagertherapeutics.com

Headquarters

Lexington, MA 02421, US

VYGR Financials

Key Financial Metrics (TTM)

Gross Margin

-178.62%

Operating Margin

-349.16%

Net Income Margin

-319.61%

Return on Equity

-55.97%

Return on Capital

-56.69%

Return on Assets

-53.18%

Earnings Yield

-64.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$183.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

60.42M

Volume

590.61K

Avg. Volume

640.92K

Financials (TTM)

Gross Profit

-$65.19M

Operating Income

-$127.42M

EBITDA

-$112.54M

Operating Cash Flow

-$127.99M

Capital Expenditure

-$1.95M

Free Cash Flow

-$129.94M

Cash & ST Invst.

$141.48M

Total Debt

$34.57M

Voyager Therapeutics Performance Analysis

Voyager Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 40,907,0009.3%
20232023-12-31USD 250,008,000511.2%
20242024-12-31USD 80,001,000-68.0%
20252025-12-31USD 40,374,000-49.5%
Voyager Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-19.7%
Q32025-09-30157.0%
Q42025-12-3114.7%
Q12026-03-31-83.1%
Voyager Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.21-36.0%
20232023-12-31USD 2.97N/A
20242024-12-31USD -1.13N/A
20252025-12-31USD -2.0481.0%
Voyager Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-7.5%
Q32025-09-3017.5%
Q42025-12-31N/A
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.59M

-59.9%

Gross Profit

$1.66M

+106.6%

Gross Margin

64.06%

N/A

Market Cap

$183.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.30M

N/A

Employees

141

N/A

Net Income

-$27.94M

+9.9%

EBITDA

-$26.99M

+9.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$141.48M

-40.1%

Total Debt

$34.57M

-17.7%

Accounts Receivable

$1.65M

-22.0%

Inventory

$0.00

N/A

Long Term Debt

$27.20M

-21.3%

Short Term Debt

$7.36M

-0.9%

Return on Assets

-53.18%

N/A

Return on Invested Capital

-63.12%

N/A

Free Cash Flow

-$33.43M

+13.3%

Operating Cash Flow

-$33.42M

+11.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PYXSPyxis Oncology, Inc.
$2.92+0.34%
ARCTArcturus Therapeutics Holdings Inc.
$5.79+0.70%
SGMTSagimet Biosciences Inc.
$7.04-3.16%
TRDAEntrada Therapeutics, Inc.
$6.55+12.35%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About VYGR

What is the current price of Voyager Therapeutics?

Voyager Therapeutics is trading at $3.00 per share.

What is the 52-week range for Voyager Therapeutics?

Over the past 52 weeks, Voyager Therapeutics has traded between $2.88 and $5.55.

How much debt does Voyager Therapeutics have?

As of the most recent reporting period, Voyager Therapeutics reported total debt of $34.57M.

How much cash does Voyager Therapeutics have on hand?

Voyager Therapeutics reported $43.31M in cash and cash equivalents in its most recent financial results.

What is Voyager Therapeutics’s dividend yield?

Voyager Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services